GC Cell announced on Tuesday that it has filed a patent for immunotherapy targeting solid tumors.

This patent, based on GC Cell's Chimeric Antigen Receptor Natural Killer (CAR-NK) platform, represents a pipeline developed with Claudin 18.2 as the Target, expanding its potential applications in the solid tumor field.

Claudin 18.2, a protein expressed in various solid tumors including gastric, pancreatic, and esophageal cancers, has recently caught the attention of the global pharmaceutical and biotech industries as a key therapeutic Target.

Unlike Chimeric Antigen Receptor T-cell (CAR-T) therapies that use a patient's own cells, CAR-NK therapies utilize cells from healthy donors. This approach allows for mass production of a universal treatment, offering a significant advantage.

The therapy is expected to provide high safety due to the innate immune properties of NK cells. It's also seen as a promising alternative that could reduce treatment costs and improve patient access through more efficient manufacturing and supply processes.

Won Sung-yong, Chief Executive Officer (CEO) of GC Cell, stated that this patent is another milestone in the ongoing research and development of the CAR-NK platform-based solid tumor pipeline. He added that it will continue to strengthen the global competitiveness through further research and development in this area.

GC Cell announced on Tuesday that it has filed a patent for immunotherapy targeting solid …

GC Cell's CAR-NK: Revolutionizing Solid Tumor Treatment with New Patent